- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that it has been granted United States Patent No. 7,252,940, titled "Abasic site endonuclease assay" from the U.S. Patent and Trademark Office. The technology described in the patent extends the underlying proprietary real-time PCR technology used in the Company's MGB Alert® products to a new product offering that has been commercialized as research reagents for use in replication validation following genome wide scanning in pharmaceutical and biotechnology industry labs. This technology is also ideal for genetic analysis in multiplex formats of complex genetic diseases.
The unique construct of these assay reagents provides researchers with a method for high throughput validation of SNPs (single nucleotide polymorphisms) discovered during genome wide scanning. The goal of many genome wide scanning projects is to identify SNPs associated with particular diseases, such as diabetes or heart failure, in order to identify therapeutic targets or develop diagnostic assays. In order to establish clear disease association, SNPs are validated across large sample populations, often on the order of tens of thousands. This newly patented technology provides the ability to test large numbers of SNPs in parallel across a large number of samples to complete validation in a relatively rapid manner.
Nanogen has also been awarded U.S. Patent No. 7,205,105, "Real-time linear detection probes: sensitive 5'-minor groove binder-containing probes for PCR analysis," related to the probes employed in its MGB Alert® line of reagents. These probes are an important part of the Company's proprietary product offering designed to assist clinical laboratories in developing molecular diagnostic tests that will detect genetic sequences associated with pathogens including those often tested in immunocompromised patients such as cytomegalovirus, Epstein-Barr virus, and enterovirus.
About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.
For more information, please click here
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
Kelly Goodwin, Marketing Communications, 858-410-4688
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016
Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016
NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016